Fibromyalgia on Rheumatology Network

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

https://www.hcplive.com/view/autoimmune-inflammatory-tissue-disorders-associated-covid-19-infection

Brandon Arbiter joins the podcast to discuss the latest updates from Tidepool.

https://www.hcplive.com/view/diabetes-dialouge-tidepool-updates-with-brandon-arbiter

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

https://www.hcplive.com/view/covid-19-pandemic-linked-to-29-higher-risk-of-dyslipidemia-study-finds

Although children on baclofen had numerically greater improvements in rumination syndrome symptoms than those on placebo, the group difference was insignificant.

https://www.hcplive.com/view/baclofen-does-not-significantly-improve-rumination-syndrome-symptoms-children

Enhanced growing-up milk improved DHA, choline, and lutein levels and working memory in toddlers over 6 months, according to a study presented at NASPGHAN 2024.

https://www.hcplive.com/view/toddlers-nutrition-executive-control-benefits-enhanced-growing-up-milk

A sample of some of the most significant developments in pulmonology from October is featured in this Month in Review summary.

https://www.hcplive.com/view/pulmonology-month-review-october-2024

The study is one of the first to report United States IgAN incidence based on a large racially and ethnically diverse cohort.

https://www.hcplive.com/view/racial-ethnic-iga-nephropathy-stratification-provides-new-insight-us-incidence

The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.

https://www.hcplive.com/view/whole-body-mris-reveal-psa-inflammation-improvements-apremilast

The announcement by the FDA resulted from an agency review of data on oral phenylephrine and a determination of its ineffectiveness as an active ingredient.

https://www.hcplive.com/view/fda-suggests-removing-oral-phenylephrine-otc-monograph-nasal-decongestant-ingredient

The VARIPULSE platform enables AF treatment with a single device combining pulsed field ablation therapy and mapping with the CARTO 3 system.

https://www.hcplive.com/view/fda-approves-varipulse-platform-for-treatment-of-atrial-fibrillation

In this geospatial analysis, findings indicate that geographic regions with more tanning bed facilities tend to report higher melanoma rates.

https://www.hcplive.com/view/tanning-bed-access-linked-higher-rates-skin-cancer-specific-us-regions

Satish Rao, MD, PhD, explains how a stool diary app may provide incremental benefit and facilitate treatment monitoring with the vibrating capsule.

https://www.hcplive.com/view/stool-diary-app-aids-vibrating-capsule-compliance-efficacy-chronic-constipation

Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.

https://www.hcplive.com/view/filgotinib-continues-efficacy-ra-lte-studies

Work-related stress associated with adverse cardiovascular health in diverse US adult population, indicating potential risk factor for CVD prevention.

https://www.hcplive.com/view/work-related-stress-linked-to-poor-cardiovascular-health-in-us-adults

In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.

https://www.hcplive.com/view/allergy-month-in-review-october-2024

Phase 3 data shows lumateperone 42 mg significantly delayed relapse in patients with schizophrenia vs placebo, with 63% reduced relapse risk and good tolerance.

https://www.hcplive.com/view/phase-3-data-shows-lumateperone-delays-schizophrenia-relapse-longer-than-placebo

This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.

https://www.hcplive.com/view/nephrology-month-in-review-october-2024

If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024.

https://www.hcplive.com/view/fda-accepts-bla-denosumab-biosimilar

This interview with Kraft features a discussion regarding her team’s new data from the BATURA study on albuterol for patients’ asthma exacerbations.

https://www.hcplive.com/view/monica-kraft-md-discussing-phase-3b-findings-albuterol-budesonide-for-asthma

Teva presents 2 findings at Psych Congress 2024: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.

https://www.hcplive.com/view/phase-3-data-shows-tev--749-injection-improves-social-function-in-schizophrenia

Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.

https://www.hcplive.com/view/mazen-noureddin-md-differences-resmetirom-efficacy-based-body-weight-bmi

MASEF score seemed to be sensitive and effective in detecting at-risk MASH in 2 abstracts presented at the ACG 2024 Meeting.

https://www.hcplive.com/view/masef-score-may-top-fib-4-clinical-screening-early-mash-detection

Survey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.

https://www.hcplive.com/view/survey-highlights-critical-role-of-pharmacists-in-hcv-management

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

https://www.hcplive.com/view/emergency-department-hcv-screening-may-reduce-potential-hepatic-complications-lower-costs

Chronic hepatitis B patients with HBsAg

https://www.hcplive.com/view/low-hbsag-levels-during-nucleotide-analog-therapy-brings-favorable-prognostic-outcomes

Phase 3, 3b, and 4 clinical trials will provide long-term insight into the use of elafibranor in different PBC patient populations and real-world settings.

https://www.hcplive.com/view/understanding-elafibranor-iqirvo-pbc-insight-new-clinical-trials

Direct-acting antiviral agents have enabled more availability for organ transplant.

https://www.hcplive.com/view/hcv-organs-better-waitlist-survival-outcomes-transplantation

This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.

https://www.hcplive.com/view/hepatology-month-in-review-october-2024

Alcohol relapses were detected more frequently after the introduction of phosphatidylethanol in orthotopic liver transplant recipients.

https://www.hcplive.com/view/phosphatidylethanol-aids-detection-of-alcohol-relapse-post-liver-transplant

Despite the number of individuals with MASLD-related HCC without cirrhosis who report a low FIB-4, current care pathways may not identify such patients for additional assessments.

https://www.hcplive.com/view/study-highlights-limitations-clinical-pathways-masld-related-hepatocellular-carcinoma